Heart Failure Pharmacology
Sort by:
Cardiometabolic Health Congress (CMHC)
SGLT-2 Inhibitors & GLP-1 RAs in CV Risk: What Are the Beneficial Effects on Reducing CVD Events?
FEATURING
Robert Eckel
- 176 views
- January 15, 2021
Houston Methodist DeBakey Heart and Vascular Center
Top 4 Topics in Preventive Cardiology: Discussion
- 37 views
- November 15, 2022
Morristown Medical Center Cardiology & Heart Surgery
Hypertrophic Cardiomyopathy: Focus on Medical Advances and Athletic Participation
FEATURING
Matthew Martinez
- 81 views
- November 15, 2022
CVRx | Barostim
Baroreflex Activation Therapy: A Novel Approach for HFrEF Patients HFSA Symposium 2022 Discussion
- 120 views
- November 16, 2022
Keck School of Medicine of USC
Newer Therapies in Management of Chronic Heart Failure: Roles of SGLT2 Inhibitors and Vericiguat
FEATURING
Kruti Pandya
- 290 views
- December 28, 2020
26th Annual San Diego Heart Failure Symposium
Q&A: Advances in Heart Failure Management
- 25 views
- December 17, 2020
Top Ten Topics in Clinical Cardiology 2022
Panel Discussion: Genetic Testing and Lipid Management
- 31 views
- November 21, 2022
26th Annual San Diego Heart Failure Symposium
Q&A: Treating Hyperlipidemia, PAH and Other CV Diseases
- 33 views
- December 16, 2020
Houston Methodist DeBakey Heart and Vascular Center
What Is the Role of Novel Anti-Diabetic Drugs in Cardiovascular Disease?
FEATURING
Imad Hussain
- 11 views
- December 9, 2020
Cardiovascular Disease Management - 5th Annual Symposium
CDM 2017 Day 1 Discussion 1
- 9 views
- December 27, 2017